It moves to the text on this page.
  • Eisai Global
  • Contact Us
  • Site Map
Text Size

Eisai Ltd.

United Kingdom

  • Home
  • 中文
  • English
  • About Eisai
    • Chairman Message
    • President Message
    • Company Profile
    • History
    • Manufacturing
    • Quality Assurance
    • Environmental Protection
  • human health care
    • Mission、Vision、Value
    • Eisai Culture
    • CSR
  • Products
    • Neuroscience
    • Oncology(Special Care)
    • Gastrointestinal and liver diseases
    • ELN
    • Others
  • Career

News

Home  >  News

The text starts here.

News Release

01/22/2019
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME
01/12/2019
2019 Lenvatinib Launching Ceremony Jointly Held by Eisai China and MSD China
01/04/2019
NEW DRUG APPLICATION FOR PERAMPANEL DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES
11/27/2018
25 Students from China Medical University Win Eisai China Scholarships and Grants
11/22/2018
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 72ND AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
11/12/2018
EISAI LAUNCHES LENVIMA® (LENVATINIB) IN CHINA
11/07/2018
EISAI CHINA COMMENCES FULL-SCALE OPERATION OF NEW SUZHOU PLANT
10/27/2018
Eisai China Inc. Held the "2018 ADS"
10/26/2018
EISAI PRESENTS NEW DATA ON LEMBOREXANT FOR TREATMENT OF IRREGULAR SLEEP-WAKE RHYTHM DISORDER IN PATIENTS WITH ALZHEIMER’S DISEASE AT THE 11TH CLINICAL TRIALS IN ALZHEIMER’S DISEASE CONFERENCE
10/25/2018
EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Topics

Seeking Cooperation

human health care

  • Eisai Global
  • Contact Us
  • Site Map

Copyright (C) Eisai Ltd. All Rights Reserved.  沪ICP备11005394号

Page Top

  • Privacy Policy
  • Legal Notices
  • Accessibility